Understandably, the success with CD19 CAR-T cells in lymphocytic leukemia and lymphomas led to interests in extending this novel form of immunotherapy for other types of cancers targeting a variety of tumor-associated antigens. The gene discussed is CD19; the disease is lymphoid leukemia.